XNPT - BG-12 (10X-20X upside ? )Could be one of those very rare stocks with a 10X-20X upside Thus there is a good case to be made for considering XNPT a good buy based purely on Horizant, with little financing or FDA regulatory risk and further upside prospects with downside support given Arbaclofen and their L-Dopa program. The BG-12 prodrug is thus all pure upside, and it is a dramatic one. If the BG-12 program played out in the most favorable manner, then this is one of those very rare stocks with a 10X-20X upside potential per internet article.
I don't see BG-12 being anything but a slam dunk. It's the next best thing after tysabri with a 1000x better AE profile.
That being said, I don't know if 829 is really that much better than BG-12, but I certainly believe it is comparable
First phase one data for MS psoriasis drug will come out during OCT ---as they raised 45 million
following animal study---someone knows the results should be good!!! and AB drug for spastic muscles phase 3 more data--sales for REgnite in Japan -- next few weeks should be helpful to the value of xnpt
Sentiment: Strong Buy
Drug 829 must be getting good phase one results--this seems to happen everytime the investigators see that the test subjects don't have adverse reactions and the blood work yields hoped for results and Rignite is selling in Japan
as hoped---buy the rumor sell the fact
I agree and if the phase one trials show better side effects than BIIB's B12 as they did in the animal studies
10 times todays price no problem--and this could happen in the form of a buy out offer!! as the active drug has already been proved safe and effective
for MS and psoriasis via B12 studies and use in Germany